These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1333776)

  • 1. The Second International Standard for anti-poliovirus sera types 1, 2 and 3.
    Wood DJ; Heath AB
    Biologicals; 1992 Sep; 20(3):203-11. PubMed ID: 1333776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of poliovirus antigens and antibodies: microindirect haemagglutination and haemagglutination inhibition tests for poliovirus types I, II, and III.
    Esposito JJ
    Microbios; 1976; 16(63):29-36. PubMed ID: 194134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardization of poliovirus neutralizing antibody tests.
    Albrecht P; van Steenis G; van Wezel AL; Salk J
    Rev Infect Dis; 1984; 6 Suppl 2():S540-4. PubMed ID: 6330853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between indirect immunofluorescence and microneutralization for detection of antibodies to polioviruses.
    Pettit C; Minnich LL; Shehab ZM; Ray CG
    J Clin Microbiol; 1987 Jul; 25(7):1325-6. PubMed ID: 3038952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparability of poliovirus neutralizing antibody tests.
    Wood DJ; Heath AB
    Biologicals; 1992 Dec; 20(4):293-300. PubMed ID: 1339040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid methods for identification of poliovirus isolates and determination of polio neutralizing antibody titers in human sera.
    Di Lonardo A; Buttinelli G; Amato C; Novello F; Ridolfi B; Fiore L
    J Virol Methods; 2002 Mar; 101(1-2):189-96. PubMed ID: 11849697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A micrometabolic inhibition test for the estimation of poliovirus neutralizing antibodies.
    Kyriazopoulou VG; Bell EJ
    Bull World Health Organ; 1972; 47(2):171-5. PubMed ID: 4345395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of specificity of poliovirus inhibitors with inhibitor-resistant mutants of a strain of type 1 poliovirus.
    Hashimoto N
    J Immunol; 1975 Aug; 115(2):569-74. PubMed ID: 168261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine.
    Horie H; Sato M; Doi Y; Hashizume S
    Vaccine; 1996 Jan; 14(1):35-41. PubMed ID: 8821647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic characterization of poliovirus strains by neutralization kinetic studies and the modified Wecker technique.
    Nakao C
    Jpn J Med Sci Biol; 1969 Aug; 22(4):217-33. PubMed ID: 4311583
    [No Abstract]   [Full Text] [Related]  

  • 11. Intertypic cross-neutralization of polioviruses by human monoclonal antibodies.
    Uhlig H; Dernick R
    Virology; 1988 Mar; 163(1):214-7. PubMed ID: 2831657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of antipoliovirus antibodies in human and simian sera.
    Arya SC; Yetts R
    Indian J Med Res; 1973 Jul; 61(7):1025-30. PubMed ID: 4357091
    [No Abstract]   [Full Text] [Related]  

  • 13. Improvement of methods for intratypic differentiation of polioviruses. III. Neutralization test with cross-adsorbed sera for differentiation between wild and vaccine strains of polioviruses.
    Pervikov YV; Chumakov MP; Voroshilova MK; Rubin SG; Savinskaya SS; Gracheva LA
    Arch Gesamte Virusforsch; 1974; 46(1-2):71-7. PubMed ID: 4374169
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.
    van der Marel P; Hazendonk TG; Henneke MA; van Wezel AL
    Vaccine; 1983 Dec; 1(1):17-22. PubMed ID: 6099638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repertoire of antibodies against type 1 poliovirus in human sera.
    Rezapkin G; Neverov A; Cherkasova E; Vidor E; Sarafanov A; Kouiavskaia D; Dragunsky E; Chumakov K
    J Virol Methods; 2010 Nov; 169(2):322-31. PubMed ID: 20691212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
    Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
    Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INTERNATIONAL STANDARDS FOR ANTI-POLIOVIRUS SERA TYPES 1, 2 AND 3.
    LYNG J; BENTZON MW
    Bull World Health Organ; 1963; 29(6):711-20. PubMed ID: 14107743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neutralizing antibodies in the sera of persons vaccinated with intradermal poliovirus vaccine].
    Jarzabek Z; Kańtoch M
    Przegl Epidemiol; 1984; 38(3):323-6. PubMed ID: 6098935
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of poliovirus neutralizing antibodies in young adult women.
    Mayer TR; Balfour HH
    JAMA; 1981 Sep; 246(11):1207-9. PubMed ID: 6267329
    [No Abstract]   [Full Text] [Related]  

  • 20. Production and characterization of neutralizing monoclonal antibodies against poliovirus type 1, 2, and 3.
    Payment P; Trudel M; Thibodeau L; Lecomte J
    Can J Microbiol; 1989 May; 35(5):550-3. PubMed ID: 2545322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.